Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Verapamil · 4 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Verapamil Hydrochloride Extended-Release Capsules, 300 mg |
| 2 | ACTIVE_COMPARATOR | Verelan® PM Extended-Release Capsules, 300 mg |
| Name | Type | Description |
|---|---|---|
| Verapamil Hydrochloride Extended-Release Capsules, 300 mg | DRUG | 300mg, single dose fasting |
| Verelan® PM Extended-Release Capsules, 300 mg | DRUG | 300mg, single dose fasting |
| Verapamil HCL Extended-Release Capsules 300 mg | DRUG | 300mg, single dose fasting |
| Verelan® PM Extended-Release Capsules 300 mg | DRUG | 300mg, single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female. 1. Women of childbearing potential must have a negative serum (β HCG) pregnancy test performed within 21 days prior to the start of the study and on the evening prior to each dose administrat...